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ABSTRAK
Tujuan: mengetahui peran asam ursodeoksikolat terhadap hepatitis viral akut. Metode: melalui penelusuran 
literatur yang dilakukan di PubMed dan Cochrane Libarary sesuai dengan pertanyaan klinis. Setelah dilakukan 
penapisan dengan kriteria inklusi dan eksklusi, didapatkan satu meta analysis dan dua randomized controlled 
trials. Melalui telaah kritis, disimpulkan bahwa artikel tersebut memenuhi kriteria validitas dan relevansi. 
Hasil: artikel tersebut menemukan bahwa terdapat efek positif dari asam ursodeoksikolat terhadap aktivitas 
serum transaminase, dan indeks kolestasis, namun bukti yang didapatkan kurang memadai untuk menyokong 
ataupun menyanggah efek asam ursodeoksikolat terhadap perjalanan penyakit hepatitis virus akut maupun 
jumlah virus. Kesimpulan: dibutuhkan uji klinis dengan metode yang lebih baik untuk mendapatkan hasil yang 
baik dan dapat diterapkan dalam praktek klinis sehari-hari.
Kata kunci: asam ursodeoksikolat, hepatitis virus akut.
ABSTRACT
Aim: to review the role of ursodeoxycholic acid in acute viral hepatitis. Methods: following literature 
searching according to the clinical question on Pubmed and Cochrane Library. After filtered with our inclusion 
and exclusion criteria, one  meta-analysis and two randomized clinical trials are obtained. Through critical 
appraisal, it was concluded that the articles meet the criteria for validity and relevance. Results: the article 
found that there is a positive effect of ursodeoxycholic acid on the activity of serum transaminases and cholestasis 
indexes. However, there is insufficient evidence to support or to refute effects of ursodeoxycholic acid on disease’s 
course as well as the viral load. Conclusion: better method of clinical trials are needed to obtain a valid and 
applicable result for daily practice.
Key words: ursodeoxycholic acid, acute viral hepatitis.
INTRODUCTION
Hepatitis is an inflammatory liver disease 
which has become a serious problem due to 
its wide spread and complications up to now. 
Acute viral hepatitis is generally caused by 
the Hepatitis A Virus (HAV), Hepatitis B Virus 
(HBV), Hepatitis C Virus (HCV), Hepatitis D 
Virus (HDV), Hepatitis E Virus (HEV), and 
Hepatitis non A-E virus. The clinical symptoms 
are generally similar, but may be vary from 
asymptomatic to fulminant.1
There is no exact data on the epidemiology of 
the prevalence of viral hepatitis around the world. 
As an illustration, the incidence of hepatitis A 
in 2007 in the United States is approximately 
25,000 cases and the number of people with 
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hepatitis B in the world is around 350 million. 
The World Health Organization (WHO) reported 
that there are 4 million cases of acute hepatitis B 
each year with 25% of them being a carrier, and 1 
million people died from chronic active hepatitis, 
cirrhosis or primary liver cancer.2-3
Management of acute viral hepatitis is 
supportive therapy, and in some cases requires 
administration of anti-viral agent. Cholestatic 
effect of ursodeoxycholic acid has been known 
and some studies have proven its use especially 
against chronic hepatitis with cholestatic, 
however, its role against acute viral hepatitis 
remains unclear.
CLINICAL PROBLEM
Male 22 years with chief complaint of 
yellow jaundice since 3 days, before admission. 
He complained a sense of weakness, nausea, 
loss of appetite, and sub-febrile fever about 
one week before. There are no history of drugs 
consumptions, previous history of jaundice, 
intravenous drug user, and free unprotected 
sexual contact. Physical examination found 
icteric sclera and mild hepatomegaly.
Patient was diagnosed as acute hepatitis 
and planned to take a hepatitis seromarker 
examination (anti-HAV, HbsAg, anti-HCV), liver 
function (AST/ALT, GGT, ALP, bilirubin), and 
abdominal USG. The results of the blood test 
are as follows: positive IgM anti-HAV, negative 
HbsAg and anti-HCV, AST/ALT: 256/532 IU/L, 
GGT 114 IU/L, ALP 233 IU/L, total/direct/indirect 
bilirubin: 4.4/3.4/1.0 mg/dL. Abdominal USG was 
not done due to financial problem. Patient was 
diagnosed as acute hepatitis A and advised to have 
bed rest, soft diet, and given domperidone 3x10 
mg, curcuma 3x1 tab, ursodeoxycholic acid 3x1 
cap, and revisited his doctor after 1 week.
During regular visit, patient’s complaints are 
gradually decreased and had a good appetite. 
Jaundice had gradually disappeared. Laboratory 
examination of liver function are within normal 
limits and the patient was cured.
Clinical experience showed that therapy 
for acute viral hepatitis is generally supportive 
without giving ursodeoxycholic, but some 
studies have shown a positive effect on the use of 
ursodeoxycholic acid in chronic hepatitis. Thus, 
the proposed clinical questions is as follows: “Is 
there a role of ursodeoxycholic acid in acute viral 
hepatitis?”
METHODS
Literature search procedures to address the 
clinical problem is to trace online library using 
“ursodeoxycholic acid” OR “ursodeoxycholate acid” AND “acute viral hepatitis”
Cochrane Library PubMed
n = 3 n = 9
Title and abstract screening
(total n = 12)
Inclusion
 Clinical trial
 Systematic review, meta-analysis
 Study conducted in humans
 English language publication
Exclusion
3 studies
included
1 2


Animal study
Pediatrics
Short communication, editorial, commentary, letter
Figure 1. Flow chart of search strategy
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Pubmed, Google Scholar, and Cohcrane Library. 
The keywords are “ursodeoxycholic acid” OR 
“ursodeoxycholate acid” AND “acute viral 
hepatitis”.
By using this methods, 12 articles were 
obtained, the selection of title and abstract 
was conducted using inclusion and exclusion 
criteria as shown in the flowchart. Further 
research carried out manually on a list of relevant 
literature. Three articles which are relevant to 
the issue was found, which consists of 1 meta-
analysis article and 2 clinical trial articles. After 
literature selection, critical appraisal was done 
using several spect based on Center of Evidence-
Based Medicine, University of Oxford for 
therapy study.4
RESULTS
Chen et al.5 reported the results of meta-
analysis of 27 clinical trials where there is 1 
clinical trial in acute hepatitis B with a reduced 
risk of HbsAg-positive at the end of therapy, 
HBV-DNA level, and improves transaminases 
significantly. The researcher concluded that 
ursodeoxycholic acid significantly improves 
transaminases activity in chronic hepatitis B 
and C, but there is no effect on viral clearance, 
and a randomized clinical trials with better 
methodological quality is needed.
Galsky et al.6 observed 78 patients with acute 
hepatitis (59 patients with acute hepatitis B) 
which divided into 2 groups, and experimental 
group was given ursodeoxycholic acid and its 
development were followed until 12 months. 
The result showed there was a decrease in 
alanine aminotransferase, improved liver 
function significantly in experimental group. 
The author concluded that ursodeoxycholic acid 
has a positive effect on the disease course of 
acute hepatitis and may increase the clearance 
of hepatitis B virus, thus preventing chronic 
progression of the disease.
Fabris et al.7 conducted a randomized clinical 
trial to evaluated the effects ursodeoxycholic acid 
(UDCA) administration on acute viral hepatitis-
related cholestasis and the course of acute viral 
hepatitis. A total of 79 patients with acute viral 
hepatitis randomized to receive either UDCA for 
3 weeks or no treatment. Author concluded that 
UDCA significantly improves cholestatic indices 
in patient with acute viral hepatitis, but it does 
not affect the course of the illness itself.
Table 1. Critical appraisal of the studies based on criteria by centre of evidence medicine University of Oxford
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Galsky et al6 1999 RCT 78 + + + + + + + + 2
Fabris et al7 1999 RCT 79 + + + + ? + + + 2
+ stated clearly in the article; - not being done; ? not stated clearly; *levels of evidence based on The Oxford Center of 
Evidence Based Medicine 2011
Table 2. Critical appraisal of a systematic review
Authors Year
Validity
Level of 
evidencePICO Appropriate searching
Relevant 
study 
included
Quality 
assessment 
of trials
Heterogenity
Chen et al5 2003 + + + + + 2
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DISCUSSION
Acute viral hepatitis is an inflammation of 
liver cells caused by hepatitis virus with clinical 
symptoms that vary, from asymptomatic to 
fulminant. On physical examination, the general 
symptoms are jaundice, nausea, vomiting, and 
decreased appetite. Histologically, acute hepatitis 
has panlobular infiltration with mononuclear 
cells, liver cell necrosis, Kuppfer cell hyperplasia, 
and various degrees of cholestasis.
Additional investigations that can be done 
are viral serology marker examination such as 
anti-HAV, HbsAg, anti-HCV, and liver function 
examination such as AST/ALT, GGT, ALP, total/
direct/indirect bilirubin. Abdominal USG can 
also be performed but it is not very necessary in 
acute hepatitis state, except in chronic hepatitis 
with acute exacerbation. Generally, non specific 
mild hepatomegaly is found.
Management for acute hepatitis are generally 
supportive and preventing further liver damage.8
In the state of acute hepatitis, cholestasis 
occurs in almost cases which probably caused 
by massive cytolysis, and increasing hepatic cell 
damage due to effects of hydrophobic bile salt 
detergent. At that state, liver uptake and secretion 
of bile acid is disrupted, resulting in intrahepatic 
accumulation of chenodeoxycholid (CDCA) and 
deoxycholid acid (DCA) which cause hepatic 
cell damage.9
Activities of bile salt  can dissolve 
phospholipids and cholesterol, which are the main 
components of cellular membranes, but it can be 
prevented by administration of ursodeoxycholic 
acid. Several studies has reported the positive 
effects of ursodeoxycholic acid for the treatment 
of chronic liver disease with cholestasis because 
it acts as a cytoprotective, anti-apoptosis, 
membrane stabilizing, antioxidant and immune-
modulator effects.
Protective effect of ursodeoxycholic acid is 
thought to exist from modification of bile acid 
by increasing hydrophilic fraction and membrane 
cell stabilization.9-10 In addition, ursodeoxycholic 
acid increases the excretion of cytotoxic bile 
acid (CDCA, DCA) or by binding to hepatocyte 
or biliocyte membranes, thus preventing cell 
damage.11
Ursodeoxycholic acid therapy was originated 
from traditional Chinese medicine, where a 
“yutan” drug were made from bear’s dried bile 
and used as hepatobilliary medicine.10 In 1902, 
Hammarsten reported the content of bile acid 
on bear’s bile and named it ursokoleinat.12 In 
Table 3. Results of all studies
Author Results Summary
Galsky et al6 1. Elevation of alanine aminotransferase persisted more frequently in 
the placebo group (all cases, p = 0.05; hepatitis B group, p = 0.03). 
Significant rate of decline of 
the alanine aminotransferase 
and considerable clearance 
rate of hepatitis B virus.
2. Presence of hepatitis B early antigen and hepatitis B virus DNA 
(polymerase chain reaction and hybridization) at 12 months of follow-
up, was observed in 1 of 33 patients in the UDCA group and in 6 of 
25 patients in the placebo group (p = 0.02). 
Fabris et al7 Decrease in liver enzymes and bilirubin: Significant improvement of 
cholestatic indices in patient 
with acute viral hepatitis.
Statistically significant for cholestatic index 
 - ALP (P<0.01)
 - Bilirubin (P<0.05)
 - GGT (P<0.01).
Chen et al5 1. In 1 study UDCA for acute hepatitis B significantly reduced the risk of 
hepatitis B surface antigen positivity and serum HBV DNA level.
Significant decrease in the 
risk of hepatitis B surface 
antigen positivity and serum 
HBV DNA level.
2. In 1 trial, UDCA for chronic hepatitis B significantly reduced the risk of 
having abnormal serum transaminase activities at the end of treatment.
3. 25 studies of chronic hepatitis C. Bile acids significantly decreased 
the risk of having abnormal serum alanine aminotransferase activity 
at the end of treatment (RR 0.82, 95% CI 0.76 to 0.90) and follow-up 
(RR 0.91, 95% CI 0.85 to 0.98).
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1927, Shoda found its chemical element and 
named it ursodeoxycholate.13 In 1936, Iwasaki 
found the chemical structure.14  In 1975, Makino 
reported its use for bile stone dissolution.15 In 
1985, Leuschner found an improvement of liver 
function in active chronic hepatitis patient after 
administration of ursodeoxycholate acid for bile 
stone dissolution.16 In 1987, Poupon reported the 
role of ursodeoxycholate for long-term treatment 
and has been effective in primary billiary 
cirrhosis.17 Since then, there are numerous 
studies on role of ursodeoxycholic acid in liver 
disease, but the mechanism of action has not 
been clear until now.
Mechanism of ursodeoxycholate acid to liver 
via multiple interrelated pathways including 
alteration of bile acids storage, choleresis, 
immune-modulator, and cytoprotective. Role 
of cytoprotective effect in hepatic epithelium 
is to stabilize the structure of the cell and 
induction of subcellular anti-apoptotic pathways. 
Figure 2 illustrates the working mechanism of 
ursodeoxycholic acid.
Figure 2. Mechanism of action of ursodeoxycholic acid18
Figure 2 illustrates about mechanism of 
action of ursodeoxycholate as a cytoprotective 
where ursodeoxycholate acid inhibits the 
dysfunction of mitochondria by inhibiting 
Fas-death receptor activation and preventing 
apoptosis by releasing C cytochrome.
From the existing research on the role of 
ursodeoxycholic acid, we analayzed 3 studies in 
this EBCR, two RCT and a meta-analysis that 
found favourable effects in acute viral hepatitis, 
mainly seen on the biochemical parameters. Two 
studies also showed reduced number of serum 
HBV DNA level at the end of the follow up in 
group treated with UDCA versus placebo in acute 
viral hepatitis.
One study that is slightly different from 
another studies is done by Fabris et al.7 This 
study found that UDCA treatment does not 
seem to affect the course of the disease. The 
different conclusions between these studies 
were explained by differences in determinants 
assessed. Interestingly, in this study they found a 
significantly higher reduction rate for GGT, ALP 
and blirubin serum levels, which was similar 
to that observed in cholestatic liver disease. 
However, the author emphasized that cholestasis 
that occurs during acute hepatitis is transient 
in the majority of case, and therefore it is not 
comparable to that reported in cholestatic liver 
disease and its usage rationalization still requires 
further research.
CONCLUSION
Based on the results and systematic review, 
it can be concluded that there are only a few 
research on the role of ursodeoxycholic acid 
in acute viral hepatitis and a clinical trial with 
good methodology is needed in order to make the 
result valid and applicable in clinical practice.
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